Refine
Year of publication
Document Type
- Article (105)
- Preprint (10)
- Conference Proceeding (4)
- Contribution to a Periodical (3)
- Book (1)
- Working Paper (1)
Has Fulltext
- yes (124)
Is part of the Bibliography
- no (124)
Keywords
- COVID-19 (5)
- SARS-CoV-2 (4)
- Biomarkers (3)
- ACLF (2)
- Cirrhosis (2)
- Genetics (2)
- HCC (2)
- Immunology (2)
- Inflammation (2)
- NASH (2)
- risk factors (2)
- 2‑methoxyestradiol (1)
- ALK-rearranged NSCLC (1)
- AML (1)
- Acute inflammation (1)
- Acute myeloid leukemia (1)
- Advanced stage (1)
- Alzheimer’s dementia (1)
- Amyloid-beta 42 (1)
- Anal cancer (1)
- Antibiotic therapy (1)
- Artificial Intelligence (1)
- Assay variation (1)
- Aurora kinase (1)
- BCOR (1)
- BCORL1 (1)
- Biodiversity Data (1)
- Biomonitoring (1)
- Botanical Collections (1)
- Brain tumor (1)
- Burden of disease (1)
- CEP68 (1)
- CGD (1)
- CLIF-C ACLF score (1)
- CLIF-C ACLF-R score (1)
- COBAS Taqman (1)
- COMP (1)
- COVID 19 (1)
- CRISPR/Cas9 (1)
- CVD biomarker (1)
- Cancer (1)
- Cardiovascular disease (1)
- Cardiovascular disease risk (1)
- Cardiovascular diseases (1)
- Cell biology (1)
- Clinical frailty scale (1)
- Cofactors (biochemistry) (1)
- Colorectal cancer (1)
- Complicated stage (1)
- Computerlinguistik (1)
- Concurrent chemoradiotherapy (1)
- Conservation (1)
- Data sharing (1)
- Detergents (1)
- Devic disease (1)
- Devic syndrome (1)
- Devisenmarkt (1)
- Diabetes mellitus (1)
- Diagnostic markers (1)
- Digestive system (1)
- Digitization (1)
- EGFL7 (1)
- EWSR1 (1)
- Eignungsprüfung (1)
- Electronic properties and materials (1)
- Endoscopy (1)
- Experimental models of disease (1)
- Fluid overload (1)
- Frailty (1)
- Freundschaft, Begriff (1)
- Frühgeborenes (1)
- G-protein (1)
- GARCH-Prozess (1)
- Gait analysis (1)
- Gastfreundschaft (1)
- Gastfreundschaft <Motiv> (1)
- Gastfreundschaft, Begriff (1)
- Gene fusion (1)
- Generic NLP Architecture (1)
- Gomphus flavipes (1)
- HCV (1)
- HPSG Parsing (1)
- Health care resource utilization (1)
- Heme (1)
- Herbaria (1)
- Hippocampal volume (1)
- Hypertension (1)
- IE (1)
- Immunogenetics (1)
- Induction chemotherapy (1)
- Intensive care outcome (1)
- Intensive care treatment (1)
- Intestinal neoplasms (1)
- Joint loading (1)
- Kaukasische Völker (1)
- Kindheit (1)
- Kulturbeziehungen (1)
- Kunst (1)
- LEOSS (1)
- Libellen (1)
- Literatur (1)
- Liver diseases (1)
- Low birth weight infant (1)
- MN1 (1)
- MR-proADM (1)
- Machine learning (1)
- Magnetic properties and materials (1)
- Mechanisms of disease (1)
- Medizinstudium (1)
- Membrane proteins (1)
- Metabolic syndrome (1)
- Mild cognitive impairment (1)
- Molecular biology (1)
- Molecular marker (1)
- Monitoring (1)
- Mortality (1)
- Multiple choice Fragen (1)
- Multivariate analysis (1)
- NAFLD (1)
- NHEJ (1)
- NMO-IgG (1)
- NMR spectroscopy (1)
- Nephrons (1)
- Neugeborenes (1)
- Neuroepithelial (1)
- Neuromyelitis optica (1)
- Neurooncology (1)
- Obesity (1)
- Oncogenes (1)
- Oncology (1)
- Ophiogomphus cecilia (1)
- Orphan disease (1)
- Osteoarthritis (1)
- PATZ1 (1)
- Pediatric (1)
- Periodontal disease (1)
- Periodontal therapy (1)
- Phase transitions and critical phenomena (1)
- Phospho-tau (1)
- Plasminogen (1)
- Platelets (1)
- Portal veins (1)
- Prediction (1)
- Predictive model (1)
- Prostaglandin (1)
- Proteases (1)
- Protein structure (1)
- Proteolysis (1)
- Prüfungserfolg (1)
- Psychiatric disorders (1)
- RNA (1)
- RNA stem-loop structure (1)
- RNA-binding proteins (1)
- Radical nephrectomy (1)
- Ratewahrscheinlichkeit (1)
- RealTime (1)
- Renal cancer (1)
- Renal system (1)
- Research Infrastructure (1)
- Research article (1)
- Respimat® Soft Mist™ Inhaler (1)
- Respiratory signs and symptoms (1)
- Rho/Rho-kinase (1)
- S100 calcium‑binding protein B (1)
- SARS CoV 2 (1)
- SOFA (1)
- STAR GARCH (1)
- STED superresolution (1)
- STK3 (1)
- Self-expandable metal stents (1)
- Self-expandable metal stents complications (1)
- Semantics (1)
- Sepsis (1)
- Septic shock (1)
- Serum biomarker (1)
- Shallow NLP (1)
- Soft skills (1)
- Sowjetunion (1)
- Surgical and invasive medical procedures (1)
- Surgical oncology (1)
- Survival (1)
- Survival analysis (1)
- Survivin (1)
- TACE (1)
- TP53 mutation status (1)
- Tau (1)
- Taxonomy (1)
- Thrombosis (1)
- Thromboxane (1)
- Total hip arthroplasty (1)
- Translational research (1)
- Trauma (1)
- Tumor obstruction (1)
- UCN-01 (1)
- VIP1 (1)
- Validität (1)
- Veins (1)
- Viral load (1)
- Völkerverständigung (1)
- Wechselkurs (1)
- X-ray crystallography (1)
- X-ray structure analysis (1)
- XML (1)
- Zulassungskriterien (1)
- accessory proteins (1)
- acute myeloid leukemia (1)
- acute-on-chronic liver failure (1)
- admission criteria (1)
- admission test (1)
- advanced care planning (1)
- angiogenesis (1)
- anilinopyrimidine (1)
- aquaporin-4 (AQP4) antibody (1)
- bacterial translocation (1)
- benzazepinone (1)
- cell-free protein synthesis (1)
- centrosome (1)
- centrosome linker (1)
- cerebrospinal fluid (1)
- childhood (1)
- chronic granulomatous disease (1)
- cirrhosis (1)
- clinical features (1)
- comorbidities (1)
- critically ill patients (1)
- day clinic (1)
- device handling (1)
- edentulous (1)
- endothelial cell (1)
- epidemiology (1)
- examination success (1)
- fibrosis (1)
- full-arch restoration (1)
- glioblastoma (1)
- global change (1)
- guessing likelihood (1)
- habitat destruction (1)
- hematopoietic cells (1)
- hospital admission (1)
- human biology and medicine (1)
- in situ gene correction (1)
- inflammation (1)
- inhalation flow profiles (1)
- integrin (1)
- intrinsically disordered region (1)
- lactate dehydrogenase (1)
- land use (1)
- lasso regression (1)
- learning strategies (1)
- longitudinally extensive transverse myelitis (1)
- loss-of-function (1)
- low birth weight infant (1)
- magnetic resonance imaging (1)
- male (1)
- mechanical ventilation (1)
- medical studies (1)
- melanoma (1)
- mitosis (1)
- molecular docking (1)
- monitoring (1)
- mortality (1)
- mouse (1)
- multimodal complex treatment (1)
- multiple choice question (1)
- myogenic tone (1)
- myogenic vasoconstriction (1)
- networks (1)
- neurological manifestations (1)
- neutralizing antibodies (1)
- newborn infant (1)
- nomogram (1)
- non-homologous end joining (1)
- nonlinearities (1)
- nonstructural proteins (1)
- offene Fragen (1)
- peri-implant disease (1)
- personalized medicine (1)
- premature infant (1)
- preschool children (1)
- prevalence (1)
- prognostic factor (1)
- protein kinase inhibitor (1)
- pulmonary failure (1)
- recurrent optic neuritis (1)
- respiratory disease (1)
- respiratory failure (1)
- risk factor progression (1)
- risk stratification (1)
- rootletin (1)
- sequential ALK-inhibitor therapy (1)
- short essay questions (1)
- signal transduction (1)
- single best choice question (1)
- soft skills (1)
- sorafenib (1)
- spike protein (1)
- stage (1)
- structural proteins (1)
- studentisches Lernverhalten (1)
- sulfamide (1)
- survival (1)
- systematic review (1)
- technical and fundamental trading (1)
- treatment (1)
- validity (1)
- variants of concern (1)
- vascular smooth muscle (1)
Institute
- Medizin (66)
- Physik (34)
- Biochemie, Chemie und Pharmazie (6)
- Biowissenschaften (5)
- Biochemie und Chemie (3)
- Pharmazie (3)
- Präsidium (3)
- Senckenbergische Naturforschende Gesellschaft (3)
- Biodiversität und Klima Forschungszentrum (BiK-F) (2)
- Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit (ZAFES) (2)
Despite a high clinical need for the treatment of colorectal carcinoma (CRC) as the second leading cause of cancer-related deaths, targeted therapies are still limited. The multifunctional enzyme Transglutaminase 2 (TGM2), which harbors transamidation and GTPase activity, has been implicated in the development and progression of different types of human cancers. However, the mechanism and role of TGM2 in colorectal cancer are poorly understood. Here, we present TGM2 as a promising drug target.
In primary patient material of CRC patients, we detected an increased expression and enzymatic activity of TGM2 in colon cancer tissue in comparison to matched normal colon mucosa cells. The genetic ablation of TGM2 in CRC cell lines using shRNAs or CRISPR/Cas9 inhibited cell expansion and tumorsphere formation. In vivo, tumor initiation and growth were reduced upon genetic knockdown of TGM2 in xenotransplantations. TGM2 ablation led to the induction of Caspase-3-driven apoptosis in CRC cells. Functional rescue experiments with TGM2 variants revealed that the transamidation activity is critical for the pro-survival function of TGM2. Transcriptomic and protein–protein interaction analyses applying various methods including super-resolution and time-lapse microscopy showed that TGM2 directly binds to the tumor suppressor p53, leading to its inactivation and escape of apoptosis induction.
We demonstrate here that TGM2 is an essential survival factor in CRC, highlighting the therapeutic potential of TGM2 inhibitors in CRC patients with high TGM2 expression. The inactivation of p53 by TGM2 binding indicates a general anti-apoptotic function, which may be relevant in cancers beyond CRC.
Although overexpression and hyperactivity of protein kinases are causative for a wide range of human cancers, protein kinase inhibitors currently approved as cancer drugs address only a limited number of these enzymes. To identify new chemotypes addressing alternative protein kinases, the basic structure of a known PLK1/VEGF-R2 inhibitor class was formally dissected and reassembled. The resulting 7-(2-anilinopyrimidin-4-yl)-1-benzazepin-2-ones were synthesized and proved to be dual inhibitors of Aurora A kinase and VEGF receptor kinases. Crystal structures of two representatives of the new chemotype in complex with Aurora A showed the ligand orientation in the ATP binding pocket and provided the basis for rational structural modifications. Congeners with attached sulfamide substituents retained Aurora A inhibitory activity. In vitro screening of two members of the new kinase inhibitor family against the cancer cell line panel of the National Cancer Institute (NCI) showed antiproliferative activity in the single-digit micromolar concentration range in the majority of the cell lines.
Acute myeloid leukemia (AML) is characterized by uncontrolled proliferation and accumulation of immature myeloblasts, which impair normal hematopoiesis. While this definition categorizes the disease into a distinctive group, the large number of different genetic and epigenetic alterations actually suggests that AML is not a single disease, but a plethora of malignancies. Still, most AML patients are not treated with targeted medication but rather by uniform approaches such as chemotherapy. The identification of novel treatment options likely requires the identification of cancer cell vulnerabilities that take into account the different genetic and epigenetic make-up of the individual tumors. Here we show that STK3 depletion by knock-down, knock-out or chemical inhibition results in apoptotic cells death in some but not all AML cell lines and primary cells tested. This effect is mediated by a premature activation of cyclin dependent kinase 1 (CDK1) in presence of elevated cyclin B1 levels. The anti-leukemic effects seen in both bulk and progenitor AML cells suggests that STK3 might be a promising target in a subset of AML patients.
Background & Aims: Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are increasingly a cause of cirrhosis and hepatocellular carcinoma globally. This burden is expected to increase as epidemics of obesity, diabetes and metabolic syndrome continue to grow. The goal of this analysis was to use a Markov model to forecast NAFLD disease burden using currently available data.
Methods: A model was used to estimate NAFLD and NASH disease progression in eight countries based on data for adult prevalence of obesity and type 2 diabetes mellitus (DM). Published estimates and expert consensus were used to build and validate the model projections.
Results: If obesity and DM level off in the future, we project a modest growth in total NAFLD cases (0–30%), between 2016–2030, with the highest growth in China as a result of urbanization and the lowest growth in Japan as a result of a shrinking population. However, at the same time, NASH prevalence will increase 15–56%, while liver mortality and advanced liver disease will more than double as a result of an aging/increasing population.
Conclusions: NAFLD and NASH represent a large and growing public health problem and efforts to understand this epidemic and to mitigate the disease burden are needed. If obesity and DM continue to increase at current and historical rates, both NAFLD and NASH prevalence are expected to increase. Since both are reversible, public health campaigns to increase awareness and diagnosis, and to promote diet and exercise can help manage the growth in future disease burden.
Lay summary: Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis can lead to advanced liver disease. Both conditions are becoming increasingly prevalent as the epidemics of obesity and diabetes continue to increase. A mathematical model was built to understand how the disease burden associated with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis will change over time. Results suggest increasing cases of advanced liver disease and liver-related mortality in the coming years.
Background and Aims. Systemic treatment with sorafenib has been the standard of care (SOC) in patients with advanced Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) for more than a decade. TACE has been reported to allow better local tumor control in selected patients with BCLC stage C HCC. Methods. A retrospective analysis of patients with BCLC stage C HCC that were treated with sorafenib and TACE was conducted; they were compared to BCLC stage C patients treated either with TACE or sorafenib in the same period of time outside a clinical trial. Results. A total of 201 patients with BCLC stage C were identified, who were treated with either sorafenib and TACE (group A; n = 54), sorafenib (group B; n = 82) or TACE (group C; n = 65). No significant difference in baseline characteristics was observed. Time to progression was 7.0 months (95% CI: 4.3–9.7), 4.1 months (95% CI: 3.6–4.7) and 5.0 months (95% CI: 2.9–7.1) in groups A, B and C, respectively, and overall survival was 16.5 months (95% CI: 15.0–18.1), 8.4 months (95% CI: 6.0–10.8) and 10.5 months (95% CI: 7.5–13.6), respectively (group A vs. group B: p < 0.001; group A vs. group C: p = 0.0023). Adverse events of grade 3/4 occurred in 34% of patients in group A. Conclusions. Although sorafenib is a SOC in patients with BCLC stage C HCC, TACE is frequently used as an additional locoregional treatment in selected patients. This combined approach resulted in a significant overall survival benefit in selected patients, although randomized trials have not yet proven this benefit.
Background & Aims: NAFLD is a growing health concern. The aim of the Fatty Liver Assessment in Germany (FLAG) study was to assess disease burden and provide data on the standard of care from secondary care. Methods: The FLAG study is an observational real-world study in patients with NAFLD enrolled at 13 centres across Germany. Severity of disease was assessed by non-invasive surrogate scores and data recorded at baseline and 12 months. Results: In this study, 507 patients (mean age 53 years; 47% women) were enrolled. According to fibrosis-4 index, 64%, 26%, and 10% of the patients had no significant fibrosis, indeterminate stage, and advanced fibrosis, respectively. Patients with advanced fibrosis were older, had higher waist circumferences, and higher aspartate aminotransferase and gamma-glutamyltransferase as well as ferritin levels. The prevalence of obesity, arterial hypertension, and type 2 diabetes increased with fibrosis stages. Standard of care included physical exercise >2 times per week in 17% (no significant fibrosis), 19% (indeterminate), and 6% (advanced fibrosis) of patients. Medication with either vitamin E, silymarin, or ursodeoxycholic acid was reported in 5%. Approximately 25% of the patients received nutritional counselling. According to the FibroScan-AST score, 17% of patients presented with progressive non-alcoholic steatohepatitis (n = 107). On follow-up at year 1 (n = 117), weight loss occurred in 47% of patients, of whom 17% lost more than 5% of body weight. In the weight loss group, alanine aminotransferase activities were reduced by 20%. Conclusions: This is the first report on NAFLD from a secondary-care real-world cohort in Germany. Every 10th patient presented with advanced fibrosis at baseline. Management consisted of best supportive care and lifestyle recommendations. The data highlight the urgent need for systematic health agenda in NAFLD patients. Lay summary: FLAG is a real-world cohort study that examined the liver disease burden in secondary and tertiary care. Herein, 10% of patients referred to secondary care for NAFLD exhibited advanced liver disease, whilst 64% had no significant liver scarring. These findings underline the urgent need to define patient referral pathways for suspected liver disease.
Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis
(2017)
Background: Refractory ascites (RA) is a frequent complication of cirrhosis, requiring large volume paracentesis or placement of a transjugular intrahepatic portosystemic shunt (TIPSS). The automated low-flow ascites pump (alfapump, Sequana Medical AG, Zurich, Switzerland) is an innovative treatment option for patients with RA.
Aim: To assess safety and efficacy of this treatment in patients with a contraindication to TIPSS.
Methods: Fifty-six patients (43 males; mean age 62 years) from centres in Germany, Switzerland, UK and Spain were included and followed for up to 24 months. Complications, device deficiencies, paracentesis frequency and patient survival were recorded.
Results: At the time of this analysis, 3 patients completed the 24-month observation period, monitoring of 3 was ongoing, 9 underwent liver transplantation, 17 patients were withdrawn due to serious adverse events and 23 patients died. Most frequently observed technical complication was blocking of the peritoneal catheter. Twenty-three pump-related reinterventions (17 patients) and 12 pump exchanges (11 patients) were required during follow-up. The pump system was explanted in 48% of patients (in 17 patients due to serious adverse events, in 9 at the time of liver transplantation and in 1 due to recovery from RA). Median frequency of paracentesis dropped from 2.17 to 0.17 per month.
Conclusions: The alfapump can expand therapeutic options for cirrhotic patients with RA. Continuous drainage of ascites in a closed loop automated system led to significant reduction in paracentesis frequency. Technical and procedural improvements are required to reduce the rate of adverse events and reinterventions.
Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis
(2019)
Background: Prostanoids are important regulators of platelet aggregation and thrombotic arterial diseases. Their involvement in the development of portal vein thrombosis, frequent in decompensated liver cirrhosis, is still not investigated.
Methods: Therefore, we used pro-thrombotic venous milieu generation by bare metal stent transjugular intrahepatic portosystemic shunt insertion, to study the role of prostanoids in decompensated liver cirrhosis. Here, 89 patients receiving transjugular intrahepatic portosystemic shunt insertion were included in the study, and baseline levels of thromboxane B2, prostaglandin D2 and prostaglandin E2 were measured in the portal and the hepatic vein.
Results: While the hepatic vein contained higher levels of thromboxane B2 than the portal vein, levels of prostaglandin E2 and D2 were higher in the portal vein (all P<0.0001). Baseline concentrations of thromboxane B2 in the portal vein were independently associated with an increase of portal hepatic venous pressure gradient during short term follow-up, as an indirect sign of thrombogenic potential (multivariable P = 0.004). Moreover, severity of liver disease was inversely correlated with portal as well as hepatic vein levels of prostaglandin D2 and E2 (all P<0.0001).
Conclusions: Elevated portal venous thromboxane B2 concentrations are possibly associated with the extent of thrombogenic potential in patients with decompensated liver cirrhosis.
Trial registration: ClinicalTrials.gov identifier: NCT03584204.
233U is the fissile nuclei in the Th-U fuel cycle with a particularily small neutron capture cross setion which is on average about one order of magnitude lower than its fission cross section. Hence, the measurement of the 233U(n, γ) cross section relies on a method to accurately distinguish between capture and fission γ-rays. A measurement of the 233U α-ratio has been performed at the n_TOF facility at CERN using a so-called fission tagging setup, coupling n_TOF 's Total Absorption Calorimeter with a novel fission chamber to tag the fission γ-rays. The experimental setup is described and essential parts of the analysis are discussed. Finally, a preliminary 233U α-ratio is presented.
233U is of key importance among the fissile nuclei in the Th-U fuel cycle. A particularity of 233U is its small neutron capture cross-section, which is on average about one order of magnitude lower than the fission cross-section. The accuracy in the measurement of the 233U capture cross-section depends crucially on an efficient capture-fission discrimination, thus a combined set-up of fission and γ-detectors is needed. A measurement of the 233U capture cross-section and capture-to-fission ratio was performed at the CERN n_TOF facility. The Total Absorption Calorimeter (TAC) of n_TOF was employed as γ-detector coupled with a novel compact ionization chamber as fission detector. A brief description of the experimental set-up will be given, and essential parts of the analysis procedure as well as the preliminary response of the set-up to capture are presented and discussed.